Last Updated: September 25, 2026

Amlodipine besylate; indapamide; telmisartan - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for amlodipine besylate; indapamide; telmisartan and what is the scope of freedom to operate?

Amlodipine besylate; indapamide; telmisartan is the generic ingredient in one branded drug marketed by Azurity and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for amlodipine besylate; indapamide; telmisartan
International Patents:73
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:amlodipine besylate; indapamide; telmisartan at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for amlodipine besylate; indapamide; telmisartan
Generic Entry Date for amlodipine besylate; indapamide; telmisartan*:
Constraining patent/regulatory exclusivity:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for amlodipine besylate; indapamide; telmisartan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Azurity WIDAPLIK amlodipine besylate; indapamide; telmisartan TABLET;ORAL 219423-002 Jun 5, 2025 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Azurity WIDAPLIK amlodipine besylate; indapamide; telmisartan TABLET;ORAL 219423-003 Jun 5, 2025 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Azurity WIDAPLIK amlodipine besylate; indapamide; telmisartan TABLET;ORAL 219423-001 Jun 5, 2025 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Azurity WIDAPLIK amlodipine besylate; indapamide; telmisartan TABLET;ORAL 219423-002 Jun 5, 2025 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Azurity WIDAPLIK amlodipine besylate; indapamide; telmisartan TABLET;ORAL 219423-002 Jun 5, 2025 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for amlodipine besylate; indapamide; telmisartan

Country Patent Number Title Estimated Expiration
Australia 2018213147 Compositions for the treatment of hypertension ⤷  Start Trial
Australia 2019309329 Compositions for the treatment of hypertension ⤷  Start Trial
Australia 2023274064 Compositions for the treatment of hypertension ⤷  Start Trial
Australia 2025201831 Compositions for the treatment of hypertension ⤷  Start Trial
Australia 2025287416 Compositions for the treatment of hypertension ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for amlodipine besylate; indapamide; telmisartan

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1915993 C300625 Netherlands ⤷  Start Trial PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
0502314 C300478 Netherlands ⤷  Start Trial PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
0678503 C300499 Netherlands ⤷  Start Trial PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
0503785 CA 2011 00026 Denmark ⤷  Start Trial PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
1507558 2012/018 Ireland ⤷  Start Trial PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.